Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children
18 results
1 - 18
Addition of long‐acting beta2‐agonists to inhaled corticosteroids for chronic asthma in children- Long‐acting beta2‐agonists as an inhaled corticosteroid‐sparing agent for chronic asthma in adults and children
- Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma
- Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid: Cochrane systematic review
- Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma
- Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
- Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
- Stopping long‐acting beta2‐agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids
- Inhaled steroids with and without regular formoterol for asthma: serious adverse events
- Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
- Patient‐ and parent‐initiated oral steroids for asthma exacerbations
- Inhaled steroids with and without regular salmeterol for asthma: serious adverse events